Bright Minds Biosciences (BMB) is an American pharmaceutical company which is developing serotonin 5-HT2 receptor agonists for potential medical use.
It has a particular focus on serotonin 5-HT2C receptor agonists, for instance to treat rare epilepsies and other conditions. Another area of focus for the company is serotonergic psychedelics and non-hallucinogenic psychoplastogens.
The company was co-founded by Ian McDonald and Gideon Shapiro. The lead scientist at Bright Minds Biosciences was previously Alan Kozikowski. Bright Mind Biosciences was founded in 2017 and its headquarters are in New York City, New York.
Drug candidates Bright Minds Biosciences' drug candidates include the following:
+ Bright Minds Biosciences drug candidates Drug Action Structural scaffold Indications Highestphase Ref BMB101 Selective serotonin 5-HT2C receptor biased agonist (Gq over β-arrestin) Phenylcyclopropylmethylamine Absence epilepsy, binge-eating disorder, Dravet syndrome, Lennox–Gastaut syndrome, Pitt–Hopkins syndrome, Prader–Willi syndrome, and Rett syndrome Phase 2 (entering phase 3) BMB105 Selective serotonin 5-HT2C receptor biased agonist (Gq over β-arrestin) Phenylcyclopropylmethylamine Prader–Willi syndrome Phase 1 BMB201 Serotonin 5-HT2A and 5-HT2C receptor agonist, other actions (non-hallucinogenic psychoplastogen; prodrug of BMB-A39a) Tryptamine Depressive disorders, pain Preclinical BMB202 Selective serotonin 5-HT2A receptor agonist (serotonergic psychedelic) N-Benzylphenethylamine Depressive disorders, post-traumatic stress disorder (PTSD) Preclinical
The company has also patented azepinoindoles acting as potent serotonin 5-HT2 receptor agonists and psychedelics, such as Pharm-136.
See also List of psychedelic pharmaceutical companies List of investigational hallucinogens and entactogens
References
External links
Bright Minds Biosciences - Google Patents